Maze Therapeutics vs MeiraGTx
MAZE and MGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MAZE and MGTX compare
Maze Therapeutics is the larger company, worth 2.2 times as much as MeiraGTx ($1.9B against $882M).
MeiraGTx scores higher on the StockData Score (10 against 4 for Maze Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MAZE | MGTX |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $882M |
| Share price | $34.33 | $9.18 |
| Change, 1 year | 5.4% | 6.0% |
| Change, 5 years | – | −50.8% |
| Beta (5Y) | 0.87 | 1.58 |
| Employees | 141 | 403 |
| StockData Score | ||
| Total score | 4 | 10 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 11.5× |
| P/S | – | 2.2× |
| P/B | 4.4× | – |
| EV/EBITDA | – | 4.3× |
| FCF yield | −6.0% | −0.34% (better) |
| Fair value | – | $27.21 |
| Margin of safety | – | 66.3% |
| Growth | ||
| Revenue growth (TTM) | – | 1366% |
| Revenue growth, 5Y average | – | 39.2% |
| Profitability | ||
| Operating margin | – | 44.8% |
| Net margin | – | 19.5% |
| FCF margin | – | −0.74% |
| Return on equity | −37.5% | – |
| Return on invested capital | −353% | – |
| Financial health | ||
| Debt / equity | 0.09 | – |
| Net debt / EBITDA | – | −0.33 |
| Current ratio | 14.14 (better) | 4.62 |
| Altman Z-score | 11.94 (better) | 3.11 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −20.0% |
| Shareholder yield | 0.00% (better) | −20.0% |
| Ownership | ||
| Held by institutions | 105% | 82.5% |
| Held by insiders | 16.9% | 35.2% |
| Insider net buying, 12 months | −$25.0M | −$4.7M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 14.5% | 10.7% |
Go deeper
- MAZE stock overview
- MAZE income statement
- MAZE valuation and score
- MGTX stock overview
- MGTX income statement
- MGTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.